glp 1 ra cardiovascular benefits GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes Cardiovascular benefits of GLP-1 meds

These changes happen gradually over weeks, which is why starting low and adjusting upward produces better long-term adherence than aggressive dosing

OLeary PD, Hughes RA

When intra-portal insulin levels are increased (e.g., obesity, Cushings syndrome, or due to treatment with glucocorticoids and glucagon-like peptide 1 receptor agonists) or decreased (e.g., malnutrition, anorexia nervosa and type 1 diabetes mellitus), these changes secondarily alter hepatic GH sensitivity resulting in a secondary association with discordant GH and IGF-I levels (e.g., high GH/low IGF-I levels or low GH/high IGF-I levels, respectively)

Brain Res 852:374382 Lash LH (2005) Role of glutathione transport processes in kidney function

Sermorelin therapy may be considered for men experiencing changes in energy or recovery who want clinician-guided support for natural growth hormone signaling